Jeffrey Weber, MD, PhD

Senior Member Moffitt Cancer Center

Director, Donald A Adam Comprehensive Melanoma Center

Dr. Weber earned his Ph.D. in molecular cell biology from Rockefeller University, and received his M.D. from New York University. He completed his internship and residency in Medicine at the University of California, San Diego, and his fellowship in Medical Oncology at the National Cancer Institute in Bethesda, MD.

His experience includes clinical, research and teaching positions at the University of California, Irvine, and the University of Southern California where he was Chief of Medical Oncology and Associate Director for Clinical Research at the USC/Norris Comprehensive Cancer Center. Dr. Weber is currently Director of the Donald A. Adam Comprehensive Melanoma Research Center at Moffitt Cancer Center & Research Institute.

A specialist in cancer immunotherapy, Dr. Weber is principal investigator (PI) on several ongoing studies funded by the National Cancer Institute (NCI), including trials in clinical drug development, vaccines, and studies on autoimmunity and melanoma. He has been continuously NCI R01 funded for the last 16 years. Dr. Weber is also the Principal Investigator and Director of the Moffitt Skin Cancer SPORE (P50) NCI grant, a collaborative, multi-project translational research program. Dr. Weber has published more than 100 articles in the top peer-reviewed journals in his field. Dr. Weber currently sits on the scientific advisory boards of cancer-related biotechnology companies, numerous cancer institutions and foundations.

Dr. Weber’s research interests are in the field of immunotherapy for cancer. As a translational clinical investigator, Dr. Weber has performed a variety of vaccine trials, protocols involving adoptive cell therapy, and novel immunotherapy trials in melanoma patients. Clinically, he has held 10 investigator-initiated IND over the last decade, and has pursued cutting edge trials. He has been a pioneer in the clinical advancement of antibodies that induce autoimmunity as a surrogate for clinical benefit in cancer, and the management of the autoimmune side effects.

A Team-Based Approach to Optimizing Outcomes in Melanoma: Managing Immune Response-Related and Dermatologic Side Effects in Patients being Treated with Novel Therapies

Combining Emerging Immunotherapies and Targeted Agents for the Treatment of Melanoma

Mark Socinski, MD

Professor of Medicine and Cardiothoracic Surgery

University of Pittsburgh Cancer Institute

Mark A. Socinski, MD, is a professor of medicine and cardiothoracic surgery at the University of Pittsburgh School of Medicine, and serves as director of the Lung Cancer Section at the University of Pittsburgh Cancer Institute, clinical associate director of the Lung SPORE, and co-director of UPMC Lung Cancer Center of Excellence, and co-director of the Lung and Thoracic Malignancies Program. Dr. Socinski specializes in all thoracic malignancies, including small cell and non-small cell lung cancers and mesothelioma. Dr. Socinski is board-certified in internal medicine and medical oncology. He received an undergraduate degree and a medical degree at the University of Vermont in Burlington, VT. He completed a residency in internal medicine at Harvard Medical School in Boston and a fellowship in medical oncology at Dana-Farber Cancer Institute in Boston. Dr. Socinski holds memberships in numerous professional societies such as the American College of Physicians, American Society of Clinical Oncology, International Association for the Study of Lung Cancer, and the American College of Chest Physicians. Dr. Socinski serves as co-Chair of the Thoracic Malignancies Steering Committee for the National Cancer Institute. Dr. Socinski’s primary research interests reside in all aspects of clinical trials related to the thoracic oncology population. He also serves on the Respiratory Core Committee of the Cancer and Leukemia Group B (Alliance) and has been instrumental in the development of many cooperative group trials.

Testing for Genetic Mutations in Advanced NSCLC

Clinical Challenges in the Personalized Treatment of Advanced NSCLC

Daniel J. George, MD

Associate Professor of Medicine

Duke University School of Medicine

Dr Daniel George is a tenured Associate Professor of Medicine and Surgery, Divisions of Medical Oncology and Urology in the Duke University School of Medicine. He also has appointments in the Duke Clinical Research Institute and the Duke Cancer Institute where he is the Director of Genitourinary (GU) Oncology. He an internationally recognized clinical researcher and thought leader in GU malignancies, with over 100 peer-reviewed publications. His areas of research include new drug development and biomarkers of GU cancers with an emphasis on signal transduction pathways and angiogenesis. Dr George is principal investigator of the Duke site for the Department of Defense (DOD) Prostate Cancer Clinical Trials Consortium since 2006, specializing in Phase I and II studies in prostate cancer. He is also the PI of the MaRCC registry in advanced renal cell carcinoma and Co-PI of the PCF 5000, an international, multi-sponsor supported registry in advanced prostate cancer.

Nationally, Dr George has served on the ASCO scientific committee from 2010-2012 and as the program chair of the GU committee in 2012. He currently serves on two grant committees for AACR. He is the scientific leader for kidney cancer in the Alliance Cooperative Group since 2011 and serves on the Alliance GU scientific committee, NCI GU Steering Committee and the NCI Renal Task Force. He also serves as a senior editor for Clinical Cancer Research, Clinical Advances in Hematology and Oncology, and Prostate Cancer and Prostatic Diseases.

Selecting and Sequencing Therapies for Advanced Prostate Cancer

New Directions in the Management of Advanced Prostate Cancer

Michael R. Harrison, MD

Assistant Professor of Medicine

Duke University School of Medicine

Kenneth Anderson, MD

Kraft Family Professor of Medicine

Harvard Medical School

Dr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. He is a Doris Duke Distinguished Clinical Research Scientist and American Cancer Society Clinical Research Professor. After graduating from Johns Hopkins Medical School, he trained in internal medicine at John’s Hopkins Hospital, and then completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. Over the last three decades, he has focused his laboratory and clinical research studies on multiple myeloma. He has developed laboratory and animal models of the tumor in it is microenvironment which have allowed for both identification of novel targets and validation of novel targeted therapies, and has then rapidly translated these studies to clinical trials culminating in FDA approval of novel targeted therapies. His paradigm for identifying and validating targets in the tumor cell and its milieu has transformed myeloma therapy and markedly improved patient outcome. He is the recipient of many scientific and humanitarian awards including the International Myeloma Workshop Waldenstrom’s Award in 2003, the International Myeloma Foundation Robert A. Kyle Lifetime Achievement Award in 2005, the American Association for Cancer Research Joseph H. Burchenal Award in 2007, and the American Society of Hematology William Dameshek Prize in 2008. He was elected into the Johns Hopkins Society of Scholars in 2009, the Institute of Medicine of the National Academy of Sciences in 2010, and the Royal College of Physicians and of Pathologists (UK) in 2010. In 2011 he received the American Society of Clinical Oncology David A. Karnofsky Award and the Hope Funds for Cancer Research Award of Excellence in Clinical Research, and in 2012 received the Ron Burton Humanitarian Award, the Harvard Medical School Warren Alpert Foundation Prize, and the American Cancer Society Medal of Honor.

Understanding the Fundamentals: Clonal Heterogeneity of Multiple Myeloma, Implications for Treatment of Relapsed/refractory Disease

The Evolving Landscape of Treatment Options for Relapsed/Refractory MM

Watch Connect online with thousands of your peers.
Connect Engage in real-time Q&A with top factuly.
Choose Learn about the latest treatment options.
Connect Earn AMA PRA
Category 1 Credits